R MM and pPCL

Shots: Chinese NMPA received two IND applications for CT0596 to initiate P-Ib/II trials in r/r multiple myeloma (MM) & primary plasma cell leukemia (pPCL), respectively IIT in China showed favorable efficacy as of Aug 31, 2025, with 6/8 evaluable R/R MM pts achieving PR or better (3 CR/sCR, 1 VGPR, 2 PR) at an mFU…

ByRidhi RastogiDecember 29, 2025

NEWS

CARsgen Therapeutics Presents Trial Data of CT0596 for Relapsed/Refractory Multiple Myeloma (R/R MM) at ASH’25

Shots: CARsgen reported that early clinical results of CT0596, in Pts with R/R MM, were shared in ASH’25. The company plans a P-Ib registrational study in 2026, following an IND submission expected in H2'25 The P-I trial enrolled 8 pts with R/R MM who received CT0596, with a median of 4.5 prior therapy lines. Enrollment…

ByDipanshu DixitDecember 8, 2025

CARsgen Reports the NMPA’s Dual IND Application Submission for CT0596 to Initiate P-Ib/II Trials in R/R MM and pPCL

CARsgen Therapeutics Presents Trial Data of CT0596 for Relapsed/Refractory Multiple Myeloma (R/R MM) at ASH’25

Contact US

FOLLOW US